The shares are listed on the Nasdaq Global Select Market

Davis Polk advised the sales agent in connection with a new SEC-registered at-the-market offering program by Revolution Medicines, Inc. under which Revolution Medicines may issue and sell shares of its common stock for up to an aggregate amount of $250 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “RVMD.”

Based in Redwood City, California, Revolution Medicines is a clinical-stage precision oncology company focused on developing targeted therapies to inhibit frontier targets in RAS-addicted cancers.

The Davis Polk corporate team included partner Alan F. Denenberg, counsel Jason Bassetti and associate Jiachen (Lucy) Wang. The intellectual property and technology transactions team included partner David R. Bauer and associate Alison T. Chin. The tax team included partner Michael Farber and associate Tyler Scheiner. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post